

3rd/5th Floor,
YMCA Cultural Centre Building
1, Jai Singh Road, New Delhi-8
Dated 09-12-2016

To,

The Managing Director / CEO
M/s Zydus Cadila Healthcare Ltd. (ii) M/s Abbott Healthcare Pvt. Ltd. (iii) M/s Themis
(iv) M/s Wockhardt Limited (v) M/s Unimed Pharma (vi) M/s Aurolab Pharmaceuticals (vii)
M/s FDC limited and (viii) M/s Ipca Laboratories Ltd.

Subject: Representation in respect of (i) Dexamethasone 4mg/ml injection, (ii) Gentamycin 40mg /ml injection, (iii) Paracetamol Injection 150mg/ml, (iv) Hydroxypropyl Methylcellulose injection 2%, (v) Tetanus Toxoid Injection , (vi) Chloroquine Phosphate injection 40mg/ml, (vii) Metoclopramide injection 5mg/ml and (viii) Water for injection (ix) Dicyclomine Injection 10mg/ml under para 11(3).

Sir,

With reference to above, I am directed to refer to the representation (s) and request you to provide the following information in respect of the subject formulations: -

- (i) whether there is any distortion noticed in the Ceiling/ proposed ceiling prices of the mentioned formulations on account of the pack-size, which may perhaps cause some of the packs to be non-remunerative or unviable compared to other pack-sizes/ single use – multi use.
- (ii) whether there is any special feature on any product which makes this formulation different from others on account of therapeutic benefit, and the rationale for the separate ceiling price.
- (iii) your data/information in respect of overcharging notice(s) issued by NPPA, if any, for the above mentioned formulations.

2. You are therefore, requested to furnish the above details as soon as possible along with all necessary documentary evidence in support of your contention enable to NPPA to take further necessary action.

Yours faithfully



(AK Khurana)
Director (Pricing)

Copy to: (for information & necessary action please)

- (i) Apex Pharma Organisations viz. IDMA, OPPI, CII, IPA, AISSPMA, FICCI & FOPE.
- (ii) Other manufacturers/ marketing companies for the subject formulation(s).